From Zacks Investment Research: 2025-03-06 11:36:12

Axsome Therapeutics has settled a patent litigation with Hikma Pharmaceuticals regarding its narcolepsy drug, Sunosi. Jazz Pharmaceuticals had originally received approval for Sunosi as a treatment for narcolepsy in 2019. Axsome acquired U.S. rights to Sunosi from Jazz and started selling it in May 2022. The settlement terms grant Hikma a license to sell a generic version of Sunosi in the U.S. after March 1, 2040. Sunosi has become a key revenue driver for Axsome, generating $94.3 million in sales in 2024. Axsome is also evaluating Sunosi for other conditions. Additionally, Axsome currently carries a Zacks Rank #4.



Read more at Zacks Investment Research: AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals – March 6, 2025